Argatroban Market - Forecast(2021 - 2026)

Report Code: HCR 50255 Report Format: PDF + Excel (Delivery in 48 Hrs)
Argatroban Market Overview
Argatroban Market size is forecast to reach 1.37 Billion by 2025, growing a CAGR of 3.25 during the forecast period 2020-2025.Argatroban is used with aspirin to treat and prevent harmful blood clots and it blocks certain natural substances that the body uses to form blood clots. Heparin is a more commonly used thrombin inhibitor, but it results in deficiency of blood platelet count in some cases and argatroban caters to this need by acting as a thrombin inhibitor without leading to any heparin like complications are the major factors driving the growth of the market. The characteristics of hepatic mechanism is increasing the use of argatroban in the patients with renal dysfunction and this tends to increase the overall market demand of argatroban during the forecast period 2020-2025. 

Report Coverage
The report: “Argatroban Market Forecast (2019-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Argatroban Market. 

By Product: Argatroban Powder and Argatroban Injection
By Application: Heparin – induced thrombocytopenia, Percutaneous Coronary Intervention and Cerebral Arterial Thrombosis
By Geography: North America, Europe, Asia Pacific, and Rest of the World.

Key Takeaways
  • North America dominates the Argatroban Market owing to its high consumption and increasing number of patients with heptatic impairment. The Argatroban Market scope for different regions will be provided in the final report.
  • Increase of thrombosis in individuals and heparin induced thrombocytopenia is likely to aid in the market growth of argatroban.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Argatroban Market report.
  • Low molecular weight and argatroban does not induce formation of antibodies that can alter its clearance and the high cost of argatroban is set to create hurdles for the Argatroban Market.

Product- Segment Analysis
The Argatroban powder segment held the largest share in the Argatroban Market in 2019 and is estimated to grow at a CAGR of 4.37% during the forecast period 2020-2025. The growth in this segment can be attributed to the fact that argatroban  powder is a  white, odorless crystalline powder that is freely soluble in glacial acetic acid, slightly soluble in ethanol, and insoluble in acetone, ethyl acetate  and ether which is used as an anticoagulant in individuals with thrombosis and heparin-induced thrombocytopenia and its elimination half-life is about 39 and 51 minutes. It is also used to treat conditions such as heparin-induced thrombocytopenia (HIT). Heparin is a more commonly used thrombin inhibitor, but it results in deficiency of blood platelet count in some cases. It is estimated that argatroban injection which is a sterile clear, colorless to pale yellow, slightly viscous solution  and is  available in 250-mg (in 2.5-mL) single-use amber vials, with gray flip-top caps is estimated to be the fastest growing segment and is poised to register a highest CAGR during the forecast period 2020-2025.

Application - Segment Analysis
Heparin induced thrombocytopenia held major share in the Argatroban Market in 2019. This is owing to the complications of heparin therapy. There are two types of Heparin induced thrombocytopenia. Type 1 Heparin induced thrombocytopenia presents within the first 2 days after exposure to heparin, and the platelet count normalizes with continued heparin therapy. Type 1 Heparin induced thrombocytopenia is a nonimmune disorder that results from the direct effect of heparin on platelet activation. Type 2 Heparin induced thrombocytopenia is an immune-mediated disorder that typically occurs 4-10 days after exposure to heparin and has life- and limb-threatening thrombotic complications. Heparin-induced thrombocytopenia segment is set to be the fasting growing segment and is estimated to register a highest CAGR during the forecast period 2020-2025.

Geography - Segment Analysis
North America hold major share of 33.9% of total Argatroban Market followed by Asia Pacific. North America dominates the argatroban market owing to its high consumption among patients. Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Owing to its hepatic metabolism, it is used in patients with renal dysfunction and this is increasing the demand of argatroban market in the North America region. 
However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the need of argatroban which act as a thrombin inhibitor without leading to any heparin-like complications and also owing to the increase in the number of heparin-related complications among patients and rise in incidence of percutaneous coronary intervention procedures & cerebral arterial thrombosis

Drivers – Argatroban Market

  • Increase of thrombosis in individuals and heparin induced thrombocytopenia
Increase of thrombosis in individuals and heparin induced thrombocytopenia is boosting the growth of the argatroban market. Cardiology Patient Page focuses on heparin-induced thrombocytopenia (HIT), a complication of heparin therapy. Heparin induced thrombocytopenia can often be diagnosed by measuring the platelet count and PF4 antibody level in the blood. Direct thrombin inhibitors are a class of anticoagulant medications that do not cause HIT. These drugs are administered by continuous intravenous infusion. The use of argatroban in patients with HIT and HITTS is associated with improvement in clinical outcomes compared with historical controls. Argatroban offers several practical advantages over other available agents with respect to dosing, monitoring, reversibility of effect with discontinuation of the drug, and cost.
  • Argatroban as an anticoagulant in individuals
Argatroban is used as an anticoagulant in individuals is also driving the growth of the argatroban market. Individuals require long-term anticoagulation. If warfarin is chosen as the long-term anticoagulant, this poses particular challenges owing to the falsely elevated prothrombin time and INR caused by argatroban. Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Owing to hepatic metabolism, it is set to be used in patients with renal dysfunction.

Challenges – Argatroban Market

  • Low molecular weight and argatroban does not induce formation of antibodies
Some of the factors that is set to impede the growth of the argatroban  market are Low molecular weight and argatroban does not induce formation of antibodies that can alter its clearance and also owing to  increase in allergies associated with argatroban is set to to hinder the market growth.

Argatroban Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the argatroban market. In 2019, Argatroban Market share is consolidated by the top ten players present in the market. Argatroban top 10 companies are Pfizer, GlaxoSmithKline, SANDOZ, Eagle Pharmaceuticals, Fresenius Kabi, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, and WEST-WARD, among others.

Acquisitions/Product Launches
  • In December 2018, GlaxoSmithKline acquired TESARO.
  • In November 2016, Eagle Pharmaceuticals acquire Arsia Therapeutics.

1. Argatroban Market - Overview
    1.1 Definitions and Scope
2. Argatroban Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Product 
    2.3 Key trends by Application
    2.4 Key trends by Geography
3. Argatroban Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Argatroban Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Argatroban Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Argatroban Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Argatroban Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Argatroban Market – By Product (Market Size –$Million/$Billion)
    8.1 Argatroban Powder
    8.2 Argatroban Injection
9. Argatroban Market – By Application (Market Size –$Million/$Billion)
    10.1 Heparin –induced thrombocytopenia
    10.2 Percutaneous Coronary Intervention
    10.3 Cerebral arterial thrombosis
10. Argatroban Market - By Geography 
    10.1 North America
        10.1.1 U.S.
        10.1.2 Mexico
        10.1.3 Canada
    10.2 Europe
        10.2.1 U.K.
        10.2.2 France
        10.2.3 Germany
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Rest of Europe
    10.3 Asia Pacific
        10.3.1 China
        10.3.2 India
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 Australia
        10.3.6 New Zealand
        10.3.7 Rest of APAC
    10.4 Rest of the World
        10.4.1 Middle East
        10.4.2 Africa
        10.4.3 South America
11. Argatroban Market - Entropy
12. Argatroban Market – Industry/Segment Competition Landscape (Premium)
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key companies
        12.1.3 Market Share by Countries – Key Companies
        12.1.4 Best Practices for Companies
13. Argatroban Market – Key Company List by Country Premium (Premium)
14. Argatroban Market Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Global Argatroban Market, By Product Market 2019-2024 ($M)
1.1 Argatroban Powder Market 2019-2024 ($M) - Global Industry Research
1.2 Argatroban Injection Market 2019-2024 ($M) - Global Industry Research
2.Global Global Argatroban Market, By Product Market 2019-2024 (Volume/Units)
2.1 Argatroban Powder Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 Argatroban Injection Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Global Argatroban Market, By Product Market 2019-2024 ($M)
3.1 Argatroban Powder Market 2019-2024 ($M) - Regional Industry Research
3.2 Argatroban Injection Market 2019-2024 ($M) - Regional Industry Research
4.South America Global Argatroban Market, By Product Market 2019-2024 ($M)
4.1 Argatroban Powder Market 2019-2024 ($M) - Regional Industry Research
4.2 Argatroban Injection Market 2019-2024 ($M) - Regional Industry Research
5.Europe Global Argatroban Market, By Product Market 2019-2024 ($M)
5.1 Argatroban Powder Market 2019-2024 ($M) - Regional Industry Research
5.2 Argatroban Injection Market 2019-2024 ($M) - Regional Industry Research
6.APAC Global Argatroban Market, By Product Market 2019-2024 ($M)
6.1 Argatroban Powder Market 2019-2024 ($M) - Regional Industry Research
6.2 Argatroban Injection Market 2019-2024 ($M) - Regional Industry Research
7.MENA Global Argatroban Market, By Product Market 2019-2024 ($M)
7.1 Argatroban Powder Market 2019-2024 ($M) - Regional Industry Research
7.2 Argatroban Injection Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Argatroban Market Revenue, 2019-2024 ($M)
2.Canada Argatroban Market Revenue, 2019-2024 ($M)
3.Mexico Argatroban Market Revenue, 2019-2024 ($M)
4.Brazil Argatroban Market Revenue, 2019-2024 ($M)
5.Argentina Argatroban Market Revenue, 2019-2024 ($M)
6.Peru Argatroban Market Revenue, 2019-2024 ($M)
7.Colombia Argatroban Market Revenue, 2019-2024 ($M)
8.Chile Argatroban Market Revenue, 2019-2024 ($M)
9.Rest of South America Argatroban Market Revenue, 2019-2024 ($M)
10.UK Argatroban Market Revenue, 2019-2024 ($M)
11.Germany Argatroban Market Revenue, 2019-2024 ($M)
12.France Argatroban Market Revenue, 2019-2024 ($M)
13.Italy Argatroban Market Revenue, 2019-2024 ($M)
14.Spain Argatroban Market Revenue, 2019-2024 ($M)
15.Rest of Europe Argatroban Market Revenue, 2019-2024 ($M)
16.China Argatroban Market Revenue, 2019-2024 ($M)
17.India Argatroban Market Revenue, 2019-2024 ($M)
18.Japan Argatroban Market Revenue, 2019-2024 ($M)
19.South Korea Argatroban Market Revenue, 2019-2024 ($M)
20.South Africa Argatroban Market Revenue, 2019-2024 ($M)
21.North America Argatroban By Application
22.South America Argatroban By Application
23.Europe Argatroban By Application
24.APAC Argatroban By Application
25.MENA Argatroban By Application
26.Pfizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Sandoz Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Eagle Pharmaceutical Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Fresenius Kabi Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Teva Pharmaceutical Industry Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Mitsubishi Tanabe Pharma Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.West-Ward Pharmaceutical Corporation, Sales /Revenue, 2015-2018 ($Mn/$Bn)